3月25日,康宁杰瑞制药(09966)发布截至2024年12月31日止年度的业绩公告。公司在报告期间的总收入达到6.4亿元,相较于2023年的2.19亿元大幅度增长。销售成本为6032万元,较去年有所增长。毛利则显著提升至5.8亿元。年内溢利为1.66亿元,去年则为亏损2.11亿元,显示出公司经营的明显改善。在财务回顾中,公司的其他收入减少至6202万元,主要由于利息收入的减少,从7404万元降至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.